NCT07080697 is a NA clinical trial of Splenectomy in Acute Necrotizing Pancreatitis, sponsored by Zhejiang University.

Who is sponsoring NCT07080697?

NCT07080697 is sponsored by Zhejiang University.

What drugs are being tested in NCT07080697?

Interventions in NCT07080697: Splenectomy, Control.

What condition does NCT07080697 study?

NCT07080697 studies Acute Necrotizing Pancreatitis, Portal Hypertension.

Is NCT07080697 still recruiting?

NCT07080697 is currently recruiting now. Last updated 23 July 2025.

Last reviewed 2025-07-23 · How we verify

NCT07080697

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension

Recruiting now NA Last updated 23 July 2025

What this trial tests

NA trial testing Splenectomy in Acute Necrotizing Pancreatitis in 66 participants. Currently enrolling.

Timeline

30 July 2025

Primary endpoint
28 February 2027

29 February 2028

Quick facts

Lead sponsor	Zhejiang University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	30 July 2025
Primary completion	28 February 2027
Estimated completion	29 February 2028
Sites	1 location across China

Drugs / interventions tested

Splenectomy
Control

Conditions studied

Acute Necrotizing Pancreatitis — all drugs for Acute Necrotizing Pancreatitis →
Portal Hypertension — all drugs for Portal Hypertension →

Sponsor

Zhejiang University

Who can join

Adults 18 to 75, any sex, with Acute Necrotizing Pancreatitis or Portal Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, single-center, randomized controlled trial focusing on patients with acute necrotizing pancreatitis (ANP) complicated by pancreatic sinistral portal hypertension (PSPH). The study aims to study the impact of total splenectomy on the debridement efficacy, perioperative recovery, and prognosis of patients with ANP complicated by PSPH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07080697 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 23 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07080697.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing